Medicure Inc Asset Resilience Ratio
Medicure Inc asset resilience ratio. Medicure Inc (MPH) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MPH days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medicure Inc (2018–2019)
Asset resilience ratio of Medicure Inc from 2018 to 2019. This chart shows how Medicure Inc's Asset Resilience Ratio has changed over time. Read debt load of Medicure Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medicure Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Medicure Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Medicure Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Medicure Inc Industry Peers by Asset Resilience Ratio
Compare Medicure Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Medicure Inc Asset Resilience Ratio by Year (2018–2019)
Medicure Inc asset resilience ratio by year from 2018 to 2019. The table below shows the annual Asset Resilience Ratio data for Medicure Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$42.28 Million ≈ $30.59 Million |
-- |
| 2018-12-31 | 46.02% | CA$47.75 Million ≈ $34.54 Million |
CA$103.76 Million ≈ $75.06 Million |
-- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more